Facebook Twitter Instagram
    Thursday, March 30
    • Home
    • Affiliate Disclosure
    • FTC Statement
    • Privacy Policy
    • Disclaimer
    Facebook Twitter Instagram LinkedIn
    Cannabis illumination
    Green 85
    • Home
    • Cannabis Media

      💧🥭How to Make Cannabis Infused Flavored MCT Oil Tincture | tCheck Results ✅

      March 29, 2023

      CBC Reports on Lift & Co Cannabis Expo

      March 28, 2023

      Trouble in CT, NH hears legalization proposals, Beacon Hill bills, RI cannabis commission on its way

      March 27, 2023

      What Is Your Company Doing First if Cannabis is Legalized in 2022? The Green Rush Live

      March 26, 2023

      The Emerald Cannabis Cup founder Tim Blake on his favourite strains and the Emerald Triangle |

      March 25, 2023
    • Cannabis News

      British Crown Blocks Bermuda’s Cannabis Bill

      March 29, 2023

      Liberty Health Sciences Inc CEO George Scorsis on Acquiring US Cannabis Companies

      March 28, 2023

      Is Thailand the New Weed Capital of the World? | Foreign Correspondent

      March 27, 2023

      This Week in Cannabis News – Sept 19 to Sept 25

      March 26, 2023

      Interview w/ Ben Kovler – US Cannabis Operator Green Thumb Industries ($GTBIF, $MSOS) Yahoo Finance

      March 25, 2023
    • Cannabis Products

      How can UK and European investors invest legally in medical cannabis?

      March 29, 2023

      Creating a Recipe and Nutrition Facts Label for Cannabis Edible Products Sold in Oregon

      March 28, 2023

      Cannabis Legalization in Canada – Marijuana Use by Tenants

      March 27, 2023

      Warnings about potential cannabis candy

      March 26, 2023

      Cannabis Activism Panel discuss legalizing cannabis in the UK! Hemp & CBD Expo

      March 25, 2023
    • Shop
    Cannabis illumination
    You are at:Home»Blog»Big Pharma reportedly loses billions every time a state legalizes weed

    Big Pharma reportedly loses billions every time a state legalizes weed

    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email
    Green 85


    A recent study found that legalizing cannabis can cost pharmaceutical companies billions in sales and market share. Here’s why.


    New data shows that when a new state legalizes medical or adult-use cannabis, pharmaceutical companies operating in that state take a significant hit on the stock market.

    For the study, researchers compared stock return data from 45 major “legalization events” across California, Oklahoma, Michigan, Mississippi, and Virginia between 1996 and 2018, and defined a “legalization event” as “the day that the state governor signed cannabis (legalization) or voters approved a ballot initiative to legalize access to cannabis, either medical or recreational.”

    The findings reveal that the legalization of cannabis in those states coincided with a 1.5-2% drop in stock prices for giants like Purdue Pharma and Pfizer, among others, which amounts to roughly $3 billion in lost sales and nearly $10 billion in market share losses for the industry as a whole.

    After analyzing stock market data recorded in the immediate aftermath of cannabis legalization in legal states, researchers observed a statistically significant drop in the returns of major drug companies. The study’s authors said the trend “persists during the 20 business days following” legalization, resulting in market share losses worth billions, and a decline in post-legalization sales for Big Pharma.

    Here’s what the new data tells us

    cannabis opioids
    When faced with the choice between opioids and cannabis, many medical patients are going green. That doesn’t appear to bode well for pharmaceutical companies. (Leafly)

    The University of New Mexico’s Economics department conducted the study with help from the Finance department at California Polytechnic State University.

    Ziemowit Bednarek and Sarah Stith, the authors credited for the report titled “U.S. Cannabis Laws Projected to Cost Generic and Brand Pharmaceutical Firms Billion,” estimate that full federal cannabis legalization could result in an 11% reduction in sales of conventional pharmaceutical drugs. They also note that the legalization of adult-use cannabis impacted Big Pharma twice as much as medical marijuana legalization did during the 1996-2018 time period.

    The study suggests that pharmaceutical companies invest in the legal cannabis market instead of advocating against federal legalization. Still, most major companies have taken a different approach that veers away from legal cannabis altogether.

    Some companies are lobbying against legalization

    Purdue Pharma and Pfizer are two of many pharmaceutical giants that are actively fighting against federal cannabis legalization. In March, Purdue paid $6 billion to settle lawsuits over its role in fueling the opioid epidemic.

    Purdue Pharma and Pfizer are both members of the Community Anti-Drug Coalitions of America (CADCA), which also includes newspaper conglomerate Gannett, the NFL, which boasts the world’s most valuable sports team, and a handful of healthcare and pharmaceutical companies that oppose legalization.

    Companies lobbying against cannabis legalization thru CADCA pic.twitter.com/phiYUErT8w

    — Graham Farrar (@grahamfarrar) August 6, 2022

    Black Cannabis Magazine visualized the list of partners in a graphic that went viral this summer, pressuring the CADCA to remove the partners’ names from its website. Although Pfizer lobbies against legalization, the company is also investing in the weed industry—and its support of federal prohibition may be in alignment with its business interests.

    In December of 2021, Pfizer announced the $6.7 billion acquisition of San Diego-based Arena Pharmaceuticals. The biotech company, which already operates a drug pipeline focused on cannabinoid-related therapeutics, could provide Pfizer with a smooth entry into the legal industry.

    Resisting federal legalization could also be Pfizer’s attempt at keeping licenses limited and competition scarce as it commits more resources to Arena and other cannabis-adjacent ventures. Many multi-state weed companies continue to lobby against federal and state legalization measures that compromise their current dominance over limited license markets.

    Here’s what Big Pharma stands to lose from legalization

    When faced with the choice of weed or pills, many patients are choosing the latter. (AdobeStock)

    The Big Pharma stock study concluded: “The average change in a firm’s market value per legalization event is $63 million with a total impact on market value across firms per event of $9.8 billion… Using the historical price-to-sales ratio of drugmakers for the year associated with each legalization event, this implies a change in annual sales across all drugmakers of $3 billion per event.”

    With the opioid epidemic surging in recent years, the reality of patients who will pay for high-priced weed before taking free pain pills can’t be ignored.

    Consider Chris Goldstein, a NORML advocate who has been tweeting through a serious leg injury. Chris’ tweets illustrate exactly why Big Pharma fears expanded access to medical or recreational weed. “They tried to give me oxycontin, for free,” Goldstein wrote online in August. “Instead I’m paying out of pocket to treat my pain with cannabis.”

    When you put it like that, Big Pharma’s fears surrounding the end of cannabis prohibition could become a reality, and Americans who want to see the end of widespread opioid abuse and Big Pharma’s role in the crisis make a strong case for supporting legalization in all state and federal jurisdictions.



    Green 85
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleThe shroom edibles market proliferates underground
    Next Article Pioneering in craft cannabis

    Related Posts

    Is secondhand cannabis smoke harmful?

    March 27, 2023

    A new April 20 cannabis contest includes a $40,000 purse

    March 27, 2023

    Leafly Buzz: 13 top cannabis strains of March

    March 24, 2023
    Green 85
    Recent Posts
    • British Crown Blocks Bermuda’s Cannabis Bill
    • 💧🥭How to Make Cannabis Infused Flavored MCT Oil Tincture | tCheck Results âś…
    • How can UK and European investors invest legally in medical cannabis?
    • Liberty Health Sciences Inc CEO George Scorsis on Acquiring US Cannabis Companies
    • CBC Reports on Lift & Co Cannabis Expo
    Green 85
    Don't Miss

    British Crown Blocks Bermuda’s Cannabis Bill

    💧🥭How to Make Cannabis Infused Flavored MCT Oil Tincture | tCheck Results ✅

    How can UK and European investors invest legally in medical cannabis?

    Liberty Health Sciences Inc CEO George Scorsis on Acquiring US Cannabis Companies

    Popular Posts

    British Crown Blocks Bermuda’s Cannabis Bill

    March 29, 2023

    💧🥭How to Make Cannabis Infused Flavored MCT Oil Tincture | tCheck Results ✅

    March 29, 2023

    How can UK and European investors invest legally in medical cannabis?

    March 29, 2023
    Recent Posts
    • British Crown Blocks Bermuda’s Cannabis Bill
    • 💧🥭How to Make Cannabis Infused Flavored MCT Oil Tincture | tCheck Results âś…
    • How can UK and European investors invest legally in medical cannabis?
    • Liberty Health Sciences Inc CEO George Scorsis on Acquiring US Cannabis Companies
    • CBC Reports on Lift & Co Cannabis Expo
    Latest Posts

    New York Marijuana Legalization Bill Signed By Governor Cuomo

    April 1, 2021

    As 4/20 Passes, The Inequalities In Cannabis Policy Are Still Evident

    April 21, 2021

    NFL Marijuana Testing Drastically Scaled Back Under New CBA

    April 30, 2021
    Copyright © 2023. FOR SALE: This Domain & Website is For Sale. Please Call 360 256-1117 or Email thewaymarketing88@gmail.com For All the Details.

    Type above and press Enter to search. Press Esc to cancel.